Tag: Selumetinib

As of early 2025, two MEK inhibitor medications have received FDA approval for the treatment of certain neurofibromas. The advent of these drugs has transformed the treatment landscape for individuals with neurofibromatosis type 1 (NF1), offering a targeted, non-surgical option for specific tumor types. This is a significant shift from previous approaches and addresses the key question of **what medication is used to treat neurofibromas?**

Chronic pain is a significant symptom for many with neurofibromatosis, with some reports indicating its prevalence as high as 70% in certain populations. Knowing **what pain medication is used for neurofibromatosis** is complex, as standard analgesics are often ineffective against the distinct neuropathic pain caused by tumor growth. Effective treatment requires a multifaceted approach, often combining different medications and complementary therapies.

Neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to grow on nerves, affects approximately 1 in every 3,000 people worldwide [1.6.3, 1.6.2]. For those affected, a critical question arises: what is the best medicine for neurofibroma?

The list price for an average patient on Koselugo is estimated to be approximately $12,500 per month, though this figure can change based on dosage and is often reduced significantly through insurance and patient assistance. This high price tag makes understanding how much does Koselugo cost a critical step for families managing neurofibromatosis type 1.

In 2020, selumetinib received FDA approval as the first effective treatment for children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). But beyond its clinical success, a critical question remains: **how does selumetinib work** at a molecular level to produce these therapeutic effects?

Affecting approximately 1 in every 3,000 to 4,000 people, Neurofibromatosis type 1 (NF1) is a genetic disorder that can cause tumors to grow on nerves [1.5.7]. The newest answer to 'What is the new drug for NF1?' is mirdametinib (Gomekli), approved by the FDA in February 2025 [1.2.1].